SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Equipment >

Zenosense, Inc. (ZENO)

ZENO RSS Feed
Add ZENO Price Alert      Hide Sticky   Hide Intro
Moderator: subslover
Search This Board: 
Last Post: 9/13/2017 12:27:06 PM - Followers: 26 - Board type: Free - Posts Today: 0



NEWS JUNE17! Yahoo Finance: Zenosense, Inc. ( OTC PINK : ZENO ) has received notice of a patent issuance in the U.S.

YTD: 266%
1 Year: 141%
(04.07.2017)


 


ZenoSense (OTC:ZENO) has carved out a unique space in a revolutionary new biomedical field that is forecast to grow to $7.2 billion in the next year. ZENO is on the vanguard of this rapid growth because it’s focusing on a disease that claims the lives of 1 in 4 Americans.(1)


About Zenosense
The Revolution In Cardiac Diagnostics

Laboratory accuracy testing in the palm of your hand -
Taking diagnosis to a new, super-sensitive, nano-magnetic level

Zenosense, Inc. (OTC:ZENO) participates in the development of transformational medical diagnostic technologies: hand-held devices used at the Point of Care replacing slow and expensive laboratory testing. Our core focus through our joint venture in MIDS Medical (http://midsmed.com/) is the development and commercialisation of MIDS Cardiac™. A hand held device being developed for use at the Point of Care for the rapid testing of cardiac markers delivering results equal or superior to laboratory gold standard accuracy within minutes. A device which can revolutionize the diagnosis and management of suspected Acute Myocardial Infarction (AMI).

Our team of professionals has world class expertise and technical know-how of the application of highly specific nano magnetic particle technology to medical testing.  This knowledge, alongside their commercial experience of the Point of Care market, puts MIDS Medical in an excellent position to commercialise MIDS Cardiac™ and become the leading innovator in this field.


Laboratory
The MIDS Medical laboratory is located at the prestigious, UK Government supported Sci-Tech Daresbury campus in the UK. Sci-Tech Daresbury is internationally recognised for leading-edge scientific research and commercial development.


Good to know
Cardiovascular disease is the leading cause of death in the Western World. Accounting for more than 17 million deaths p.a. In Europe and the US alone approximately 15-20 million patients a year visit an Emergency Department (ED) reporting chest pain which must be investigated as possibly caused by a cardiac event. Every 43 seconds someone in the US has a heart attack.

Acute Myocardial Infarction (heart attack, Acute Myocardial Infraction “AMI”) affects all of us at some point in our lives, directly or indirectly, Rapid diagnosis is key; treatment in the first “Golden Hour” being crucial to survival. Equally, early “rule out” of AMI as  the cause of chest pain can save healthcare providers $billions.


Mission
Through our Joint Venture ownership in MIDS Medical we are developing MIDS Cardiac™, a cost-effective hand held Point of Care rapid cardiac diagnostic device. MIDS Medical applies patent-protected magnetic nanoparticle detection technology and world-class technical expertise.

Our development targets the delivery of a hand held device to support high sensitivity tests to identify or discount AMI (Heart Attack), with accuracy equal or better than gold standard laboratory tests, within minutes. This will significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected Acute Myocardial Infarction.

The system is designed to be used with a minimum of training; by any ER nurse or by paramedics at the scene. We believe such a device will be in universal demand; able to meet a critical medical need and rapidly penetrate a multi-billion dollar market.


MIDS Cardiac(TM)
Rapid detection of very low levels of cardiac markers with a primary focus on troponin I and T, designed to equal or exceed gold standard laboratory levels of accuracy, at the Point of Care.

>> Proof of Market (PDF) <<


Investment Highlights

  • Addressing Lethal Global Health Threat
    Co-Developing Unique Detection Device
    Strong Partnership with Sgenia Group
    Experienced, Strong Management
    Team of Highly Qualified Biologists

Key Partnership

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through its subsidiary, Zenon Biosystem. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors." The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Sgenia Group, known for sensor development and a supplier of sensors used in the Tokamak device for a significant, international nuclear fusion research project, also produces an algal contamination detector for use in water supply applications. It rapidly and effectively scans for the volatile organic compounds (VOCs) emitted by the target algae, a unique “chemical signature” that determines the presence or absence of the algae. The Sgenia detector is effectively an electronic “nose” that can smell this signature.

Zenon is using essential elements of these technology platforms in a development program for the MRSA/SA device to be developed for Zenosense.


Leadership

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors.

Carlos Jose Gil, BSc (Engineering) - President, CEO, CFO

Carlos Jose Gil joined the company in October 2013 as a member of the board. He has experience in high-level sales management and the development of sales teams in the health care sector. From 2012 to 2013, Gil served as a managing director of Porsche Car Spain. From 2009 to 2012, Gil was sales manager at Pharmaceutic Laboratory PersanFarma. From 1994 to 2009, Gil was a medical consultant in Medical Affairs and then an account manager at Pharmaceutic Laboratory Janssen-Cilag (Johnson & Johnson). Gil holds a Bachelor of Science in Chemical Science from Valencia University, Spain.


Development Team

J. Lama, MBA, BSc

J. Lama is an engineer with a Master of Business Administration and a Bachelor of Science (Physics). His experience includes material engineering, solid state physics, electronics, renewable energy, the automotive industry and developing technological business.

M. Querol, MS

M. Querol is a mechanical engineer with a Master of Science in Telecommunications Engineering. His experience includes market development of global solutions for Aeronautical, Naval and Defense sectors, market development of internalization strategy development, and market development of industrial engineering solutions.

M. I. Gil, DEA, BSc

M. I. Gil has a Master of Advanced Studies in Fluids Mechanics from Centro Politecnico Superior of University of Zaragoza in Spain, as well as a Bachelor of Telecommunication Engineering. Gil has wide experience in sensor technologies and advanced technical and software developing.

G. Roman Perez, PhD, MAS, BSc

G. Roman Perez has a PhD in physics from the Autonomous University of Madrid (UAM), with Cum Laude distinction. He also has a Master of Advanced Studies in Condensed Matter Physics, a Master of Biophysics and a Bachelor of Physics, all issued by UAM. His work has been published in several different publications and he has spoken at conferences in France, Italy, Spain and the USA.

Additional

The company will also rely upon a team of three biologists contracted to Zenon for the development of the Sgenia Products. This team is comprised of molecular biologists and biochemists specializing in bacterial physiology and genetics, clinical microbiology and molecular biology. All hold relevant PhDs, and two hold Masters, in disciplines highly relevant to optimizing the company’s sensor for the detection of MRSA/SA. The team’s combined skillset includes deep knowledge of the clinical genetics to be addressed in order to program and refine the sensor so that it can detect SA and ideally discriminate between MRSA and SA. Variously, members of the team are business (biotechnology) management qualified, have co-authored numerous scientific publications, taught as professor, have experience of the practical clinical setting in hospital and have co-invented patents for others.


Zenosense, Inc.
Avda Cortes Valencianas 58
Planta 5 46015
Valencia, Spain
Phone: 34-96-045-4202
www.Zenosense.net
Info@Zenosense.net

 

QualityStocks designed this iBox. Please see disclaimers on the QualityStocks website: http://qualitystocks.net/disclaimer.php

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
ZENO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZENO News: Quarterly Report (10-q) 08/21/2017 03:27:26 PM
ZENO News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 08/11/2017 04:42:02 PM
ZENO News: Zenosense, Inc. - MIDS Hybrid Strip Detection Testing to Commence 07/05/2017 07:54:10 AM
ZENO News: Zenosense, Inc.: Issuance of U.S. MIDS Patent 06/15/2017 07:47:53 AM
ZENO News: Amended Quarterly Report (10-q/a) 05/19/2017 03:10:30 PM
PostSubject
#1061   ZENO romanov5 09/13/17 12:27:06 PM
#1060   ZENO looks like much accumulation going on here romanov5 09/08/17 12:28:46 PM
#1059   Something brewing in the pot romanov5 08/18/17 04:45:20 PM
#1058   Agree,and news is overdue. Great to buy as subslover 08/16/17 04:20:34 PM
#1057   ZENO looks like accumulation romanov5 08/16/17 04:09:13 PM
#1056   In hibernation mode. subslover 08/14/17 09:06:31 PM
#1055   is this stock DEAD DOA romanov5 08/14/17 01:21:36 PM
#1054   Awsome, holding steady here. GrabThatCash 07/11/17 05:05:43 PM
#1053   Very nice optimistic news! Thanks for posting subslover 07/05/17 08:55:33 AM
#1052   NEWS OUT! MIDS Hybrid Strip Detection Testing to Commence hotstockpicker 07/05/17 07:58:45 AM
#1051   @subslover: I saw the information above is not hotstockpicker 06/20/17 04:58:34 AM
#1050   News out, still stayin long here GrabThatCash 06/19/17 12:00:43 PM
#1049   NEWS OUT! subslover 06/15/17 08:44:33 AM
#1048   some press release is out. hotstockpicker 06/15/17 08:38:33 AM
#1047   Then you should have made some $ if GrabThatCash 06/13/17 12:22:07 PM
#1046   Soon after my post this crashed like there Andrew23 06/12/17 03:41:35 PM
#1045   thats what I found: hotstockpicker 06/07/17 12:00:35 PM
#1044   looks legit. hotstockpicker 06/07/17 11:54:10 AM
#1043   I think it's a total P&D scam. Who joeeasy 05/22/17 11:56:45 AM
#1042   This is definitely a legit run..check the history...may Toome 05/20/17 01:49:56 PM
#1041   Looks like a legit run they are now Sweetsassy31073 05/19/17 01:53:14 PM
#1040   Is this another false run, or is this legit? Tucker50 05/19/17 11:08:18 AM
#1039   Best short of 2017 off $3 bucks Rice Krispy Gang 05/12/17 03:04:09 PM
#1038   Anyone with common sense that traded this thing Saint_Steveo 05/11/17 01:37:24 PM
#1037   Wow! Way to screw the shareholders. SamuelPro 05/04/17 03:08:41 PM
#1036   Completely. ..got burned docprep 05/03/17 05:51:28 PM
#1035   Like a Pogo stick in Quicksand? This one AD2000 05/02/17 09:14:57 PM
#1034   Yes, very much so. AlphaDog1 04/29/17 06:01:09 PM
#1033   Do y'all think this is a pump and Dhsholl 04/25/17 09:19:42 PM
#1032   ZENO 10K: notes conversion to commons at $0.007 gm99 04/25/17 11:08:28 AM
#1031   Ouch the fanny whale! Jackthehorse1926 04/24/17 01:12:21 PM
#1030   Looks like PTCO HADV EURI TRKK charts PUMP Chunky Salsa 04/24/17 01:09:32 PM
#1029   Wow! Conversion ratio: $0.007 per share? hondaboost 04/24/17 12:53:06 PM
#1028   What ashame!!!!!---from the 10K: barknbud 04/22/17 03:20:30 PM
#1027   True that but who could find a barrow? Jackthehorse1926 04/21/17 09:57:50 AM
#1026   The easiest short of 2017. You knew that Rice Krispy Gang 04/20/17 02:07:51 PM
#1025   Looking more and more like ZEROsense... sleepthief 04/20/17 12:24:33 PM
#1024   ZENO, lots of bond notes issued and was gm99 04/18/17 11:11:15 AM
#1023   ZENO, was just $0.02 last year and $0.1 hondaboost 04/18/17 10:55:40 AM
#1022   Wow, How ugly the 10-K is ! No hondaboost 04/18/17 10:54:21 AM
#1021   10k - out. Last day of extension. subslover 04/18/17 12:15:50 AM
#1020   Because the market knows the Skull & Crossbones Mierman1313 04/13/17 08:07:19 PM
#1019   markets seem to disagree with over 2 mil volume sleepthief 04/13/17 03:43:34 PM
#1018   This company is just a shell without Nothing hondaboost 04/13/17 03:27:35 PM
#1017   ZENO, 10-Q, Ugly! It was just $0.02 last hondaboost 04/13/17 12:32:45 PM
#1016   ZENO, pump to dump Again! Was pumped from gm99 04/13/17 11:49:58 AM
#1015   Smart. Jackthehorse1926 04/12/17 03:53:17 PM
#1014   Found this stock on search of EMMD. pavah 04/12/17 03:00:31 PM
#1013   Fifty cents. Come on down. willlbone 04/12/17 02:59:00 PM
#1012   Wow wth happened this was at 3.50 on monday mylar23 04/12/17 02:39:41 PM
PostSubject